Bupivacaine to reduce pain after laparoscopic hysterectomy
Official title: Effect of Trocar Site and Vaginal Cuff Bupivacaine Injection on Postoperative Pain in Patients Undergoing Total Laparoscopic Hysterectomy
Run by Gaziosmanpasa Research and Education Hospital · NCT07435909 · Data updated 2026-11-12
This trial will test whether injecting 0.5% bupivacaine around the trocar sites and into the vaginal cuff at the end of a laparoscopic hysterectomy reduces early postoperative pain for women having the operation for benign conditions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years to 75 Years |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | Gaziosmanpasa Research and Education Hospital Government |
| Locations | 1 site (Istanbul, Gaziosmanpaşa) |
| Status | Recruiting |
| Started | August 28, 2025 |
| Main results expected | June 4, 2026 |
| Study ends | June 4, 2026 |
| Registry record updated | May 27, 2026 |
| Trial ID | NCT07435909 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 35–75 scheduled for total laparoscopic hysterectomy for benign gynecologic conditions, ASA class I–II, cognitively able to report pain, and who complete the surgery laparoscopically are the intended participants.
✕Probably not a fit
Patients with suspected or confirmed malignant gynecologic disease, known allergy to bupivacaine, chronic pain syndromes or analgesic dependence, or those converted to laparotomy are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, randomized, single-blind controlled trial comparing intraoperative local infiltration of 0.5% bupivacaine at trocar entry sites and the vaginal cuff with no local anesthetic injection in patients undergoing total laparoscopic hysterectomy for benign indications. All participants receive standard postoperative analgesia while pain is measured with a visual analog scale at 1, 2, 3, 6, 12 and 24 hours after surgery. Secondary outcomes include additional analgesic requirements, time to first mobilization, time to first flatus, and length of hospital stay. The intervention delivers a total of 10 mL (5 mL 0.5% bupivacaine diluted with 5 mL saline) with targeted injections under laparoscopic visualization.
Why it matters
Potential benefit: If successful, the approach could reduce early postoperative pain and opioid use, helping patients mobilize and recover sooner.
How similar studies have gone: Previous studies of trocar-site infiltration with local anesthetic have reported mixed results, and combined trocar-site plus vaginal cuff infiltration is less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients aged 35-75 years * Scheduled for total laparoscopic hysterectomy for benign gynecologic conditions, including leiomyoma uteri, adenomyosis, abnormal uterine bleeding, endometrial pathology (non-atypical hyperplasia, endometrial thickening, or polyps), cervical intraepithelial lesions (CIN 2-3) without evidence of invasion and indicated for therapeutic hysterectomy, chronic pelvic pain, or benign uterine prolapse * American Society of Anesthesiologists (ASA) physical status class I-II * Cognitive ability sufficient to assess and report postoperative pain (no dementia or severe psychiatric disorder) * Provision of written informed consent * Completion of surgery laparoscopically as planned (no conversion to laparotomy) Exclusion Criteria: * Presence or suspicion of malignant gynecologic disease * History of allergy or hypersensitivity to bupivacaine or other amide-type local anesthetics * History of chronic pain syndrome, analgesic dependence, or regular use of opioids or nonsteroidal anti-inflammatory drugs (NSAIDs) * Severe systemic disease (e.g., uncontrolled diabetes mellitus, hepatic or renal insufficiency, or heart failure) * Neurological or psychiatric disorders that impair the ability to assess or report pain
Where it's running
-
SBÜ Gaziosmanpaşa Training and Research Hospital
Istanbul, Gaziosmanpaşa, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: serkan kumbasar, md
- Email: drserkankumbasar@hotmail.com
- Phone: 5067873216
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
Palatal Shield Technique to Reduce Pain and Improve Healing After Free Gingival Graft
This randomized trial tests whether a collagen sponge with a protective palatal shield made of flowable resin helps reduce pain and improve healing after free gingival graft harvest.
-
Perfusion Index to Measure Postoperative Pain in Kids After Adenotonsillectomy
This study tests whether the perfusion index can reliably reflect pain levels in children aged 1–12 after adenotonsillectomy, comparing standard care with an added glossopharyngeal nerve block.
-
Anterior Knee Nerves Block vs Femoral Nerve Block for Knee Arthroscopy
This trial tests whether an anterior nerves of the knee (ANK) block provides similar pain relief to a femoral nerve block after knee arthroscopy in adults, aiming to reduce quadriceps weakness.
-
Natural Biopolymer-Based Irrigant for Root Canal Cleaning
This trial tests a chitosan nanoparticle irrigant to improve cleaning and disinfection in single-rooted teeth with asymptomatic pulp necrosis undergoing endodontic treatment.
-
Postoperative Pain Trajectories After Endometriosis Surgery
This study tests how pain changes after endometriosis surgery and whether perioperative pain testing can predict who will have ongoing pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.